Zolbetuximab (Vyloy, Zolbetuximab) brief description

Zolbetuximab (trade nameVyloy, generic name Zolbetuximab) is an innovative chimeric IgG1 monoclonal antibody specifically developed for the Claudin 18.2 (CLDN18.2) target. The drug, developed by Astellas Pharmaceutical Group, is the world's first antibody drug targeting CLDN18.2. It is mainly used to treat patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma.

Zotuximab should be used under the supervision of a physician experienced in cancer treatment. Treatment is usually done in a hospital or clinic and is given by intravenous injection (drip into a vein), with each injection lasting at least 2 hours. The specific dosage and frequency of medication are determined by the patient's doctor based on the patient's specific condition and the selection of other anti-cancer drugs. Typically, patients receive zotuximab every 2 or 3 weeks, depending on other anticancer drugs chosen by their doctor.

During treatment, the patient's doctor will closely monitor the patient's response and condition to determine how many treatments are needed. The efficacy and safety of zotuximab have been verified in multiple clinical trials, but patients may still experience some adverse reactions during use, such as nausea, vomiting, and decreased appetite. Therefore, patients should fully understand the drug information before using zotuximab and use it rationally under the guidance of a doctor to ensure the safety and effectiveness of the treatment.

In summary, zotuximab, as an innovative targeted therapy, provides a new treatment option for gastric cancer patients. Rational use under the supervision of doctors is expected to bring better treatment effects and quality of life to patients. It is reported that zotuximab is currently only available in overseas markets, and the price per box is about more than 10,000 yuan. When purchasing, patients should make sure to go through formal channels and carefully check the authenticity of the medicine.